Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
49 hedge funds and large institutions have $58.1M invested in Regulus Therapeutics in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 48 → 49 (+1)
0.05% less ownership
Funds ownership: 0.5% → 0.45% (-0.05%)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
25% less capital invested
Capital invested by funds: $77.2M → $58.1M (-$19M)
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$1.08M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
+$1.07M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$414K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$105K |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.55M |
| 2 |
BC
Broadfin Capital
New York
|
-$2.94M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$543K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$433K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$255K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
51
Element Capital Management
New York
| – | -$76K | -504 | Closed |
|
52
Creative Planning
Overland Park,
Kansas
| – | -$51K | -342 | Closed |
|
|
ARTA
53
A.R.T. Advisors
New York
| – | -$31K | -207 | Closed |
|
|
FIM
54
Freedom Investment Management
Hartford,
Connecticut
| – | -$30K | -201 | Closed |
|
55
JP Morgan Chase
New York
| – | -$10K | -63 | Closed |
|
56
Bank of America
Charlotte,
North Carolina
| – | -$3.8K | -30 | -91% |
|
57
Simplex Trading
Chicago,
Illinois
| – | -$1.14K | -9 | Closed |
|
|
WTB
58
Washington Trust Bank
Spokane,
Washington
| – | +$127 | +1 | New |
|
RGLS Hedge Fund Activity: Q4 2017 in Review
49 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2017, worth a combined $58.1M — down 25% from $77.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RGLS positions and 9 closed out — a net gain of 1 holder — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.2M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $6.55M sold.
- 49 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2017, up from 48 in Q3 2017.
- Funds reported $58.1M of Regulus Therapeutics stock for Q4 2017, down 25% quarter-over-quarter.
- 10 funds opened new Regulus Therapeutics positions in Q4 2017 and 9 closed out, a net change of +1 holder.
- The largest Regulus Therapeutics buyer in Q4 2017 was Point72 Asset Management, an estimated $1.2M added.
- The largest Regulus Therapeutics seller in Q4 2017 was EcoR1 Capital, an estimated $6.55M sold.
Based on aggregated 13F filings for Q4 2017.